ABCAM PLC Publication of 2021 ARA and Notice of AGM (8031G)

TIDMABC

RNS Number : 8031G

ABCAM PLC

04 April 2022

4 April 2022

ABCAM PLC

("Abcam" or "the Company")

Publication of 2021 Annual Report and Accounts and Notice of Annual General Meeting

Cambridge, UK: Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, f ollowing release on 14 March 2022 of its final results for the 12- and 18-month periods ended 31 December 2021, the Abcam plc Annual Report and Accounts 2021 (the "Annual Report") have been published today and are available on the Abcam plc website at corporate.abcam.com .

The Annual Report will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications. Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on Abcam plc website at corporate.abcam.com .

Abcam will also release its latest Impact Report later in April. The report will be published at corporate.abcam.com/sustainability .

For further information, please contact:

 
Abcam                                                + 44 (0) 1223 696 000 
Marc Perkins, Company Secretary 
Numis - Nominated Advisor & Joint Corporate Broker   + 44 (0) 20 7260 1000 
Garry Levin / Freddie Barnfield / Duncan Monteith 
 
 
 
 Morgan Stanley - Joint Corporate Broker      [phone] 
  Tom Perry / Luka Kezic                      8000 
 

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit corporate.abcam.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAJBMTTMTIJBTT

(END) Dow Jones Newswires

April 04, 2022 02:01 ET (06:01 GMT)